Geriatric Medicine Development Market Size, Share, Trends and Forecast 2016

Submitted by: Submitted by

Views: 10

Words: 520

Pages: 3

Category: Business and Industry

Date Submitted: 03/08/2016 12:31 AM

Report This Essay

Geriatric Medicine Development Market Share and Size, Pipeline Analysis, Commercial Trends, Operational Strategies Research Report By Radiant Insights Inc.

More than 50% of prescriptions is written for people aged 65 years and older. Many older people suffer from comorbid conditions and one in three takes at least five drugs or more on a daily basis. This significantly increases the risk of Adverse Drug Events (ADEs) and hospitalization. Up to one third of emergency admissions in elderly people is drug-related.

There remains a lack of clinical data to support prescription decisions as relatively few medicines have been clinically evaluated in age-appropriate patients. In addition, many drugs are not available in formulations that are suitable for the elderly, leading to non-compliance and lack of therapeutic efficacy. In 2011, the EMA introduced its Geriatric Medicines Strategy to ensure that the medical requirements of older people are identified earlier in the drug development process. In 2012, the ICH E7 guidelines were revised to include a greater focus on involving more geriatric patients in drug trials.

Browse Detail Report With TOC @ http://www.radiantinsights.com/research/geriatric-medicine-development-carving-out-new-opportunities-to-treat-age-related-diseases

Key Reasons to Purchase

Utilize the insights from this study to analyze the barriers facing the geriatrics market

Understand the impact of drug development in this market now and in the future

Find out why regulators are paying more attention to unnecessary "exclusion criteria" and encouraging the inclusion of older people to ensure trials are age-appropriate and more representative of the real world setting.

Assess the opportunities available for companies to develop age-appropriate dosages and formulations for existing drug classes that are currently widely associated with ADEs in the elderly as well as new therapeutic prospects.

Table Of Content

Executive Summary...